Follow
Sebastien Hotte
Sebastien Hotte
Unknown affiliation
Verified email at execulink.com
Title
Cited by
Cited by
Year
A practical approach to the management of cancer patients during the novel coronavirus disease 2019 (COVID‐19) pandemic: an international collaborative group
HO Al‐Shamsi, W Alhazzani, A Alhuraiji, EA Coomes, RF Chemaly, ...
The oncologist 25 (6), e936-e945, 2020
7862020
Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with …
M Moore, HW Hirte, L Siu, A Oza, SJ Hotte, O Petrenciuc, F Cihon, ...
Annals of oncology 16 (10), 1688-1694, 2005
3672005
Current management of castrate-resistant prostate cancer
SJ Hotte, F Saad
Current oncology 17 (s2), 72-79, 2010
3162010
Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study
SJ Hotte, EW Winquist, E Lamont, M MacKenzie, E Vokes, EX Chen, ...
Journal of Clinical Oncology 23 (3), 585-590, 2005
3052005
Systemic therapy in men with metastatic castration-resistant prostate cancer: American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline
E Basch, DA Loblaw, TK Oliver, M Carducci, RC Chen, JN Frame, ...
Journal of Clinical Oncology 32 (30), 3436, 2014
3042014
Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America
WM Stadler, RA Figlin, DF McDermott, JP Dutcher, JJ Knox, WH Miller Jr, ...
Cancer: Interdisciplinary International Journal of the American Cancer …, 2010
2962010
Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer
KN Chi, SJ Hotte, EY Yu, D Tu, BJ Eigl, I Tannock, F Saad, S North, ...
Journal of clinical oncology 28 (27), 4247-4254, 2010
2892010
Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non–adenoid cystic carcinoma …
M Agulnik, EWE Cohen, RB Cohen, EX Chen, EE Vokes, SJ Hotte, ...
Journal of Clinical Oncology 25 (25), 3978-3984, 2007
2892007
A phase 1 study of mapatumumab (fully human monoclonal antibody to TRAIL-R1) in patients with advanced solid malignancies
SJ Hotte, HW Hirte, EX Chen, LL Siu, LH Le, A Corey, A Iacobucci, ...
Clinical Cancer Research 14 (11), 3450-3455, 2008
2442008
Plasma osteopontin: associations with survival and metastasis to bone in men with hormone‐refractory prostate carcinoma
SJ Hotte, EW Winquist, L Stitt, SM Wilson, AF Chambers
Cancer: Interdisciplinary International Journal of the American Cancer …, 2002
2382002
Guidelines for the management of castrate-resistant prostate cancer
F Saad, SJ Hotte
Canadian Urological Association Journal 4 (6), 380, 2010
1922010
Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-1): a randomised, controlled …
R Mesía, M Henke, A Fortin, H Minn, ACY Ancona, A Cmelak, ...
The Lancet Oncology 16 (2), 208-220, 2015
1792015
Phase II study of Triapine® in patients with metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC IND. 161)
JJ Knox, SJ Hotte, C Kollmannsberger, E Winquist, B Fisher, ...
Investigational new drugs 25, 471-477, 2007
1752007
A phase II study of sunitinib in recurrent and/or metastatic adenoid cystic carcinoma (ACC) of the salivary glands: current progress and challenges in evaluating molecularly …
NG Chau, SJ Hotte, EX Chen, SF Chin, S Turner, L Wang, LL Siu
Annals of oncology 23 (6), 1562-1570, 2012
1502012
Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate …
F Saad, S Hotte, S North, B Eigl, K Chi, P Czaykowski, L Wood, M Pollak, ...
Clinical Cancer Research 17 (17), 5765-5773, 2011
1422011
A phase I study of OGX-011, a 2′-methoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancer
KN Chi, LL Siu, H Hirte, SJ Hotte, J Knox, C Kollmansberger, M Gleave, ...
Clinical Cancer Research 14 (3), 833-839, 2008
1382008
A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer
KN Chi, SL Ellard, SJ Hotte, P Czaykowski, M Moore, JD Ruether, ...
Annals of Oncology 19 (4), 746-751, 2008
1372008
An optimized clinical regimen for the oncolytic virus PV701
SJ Hotte, RM Lorence, HW Hirte, SR Polawski, MK Bamat, JD O'Neil, ...
Clinical Cancer Research 13 (3), 977-985, 2007
1362007
Overview of phase I studies of intravenous administration of PV701, an oncolytic virus.
RM Lorence, AL Pecora, PP Major, SJ Hotte, SA Laurie, MS Roberts, ...
Current opinion in molecular therapeutics 5 (6), 618-624, 2003
1362003
The 2015 CUA-CUOG Guidelines for the management of castration-resistant prostate cancer (CRPC)
F Saad, KN Chi, A Finelli, SJ Hotte, J Izawa, A Kapoor, W Kassouf, ...
Canadian Urological Association Journal 9 (3-4), 90, 2015
1352015
The system can't perform the operation now. Try again later.
Articles 1–20